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Abstract 
 
Hyponatraemia, defined as a serum sodium concentra-
tion <135 mmol/l, is the most common disorder of body 
fuid and electrolyte balance encountered in clinical prac-
tice. It can lead to a wide spectrum of clinical symptoms, 
from subtle to severe or even life threatening, and is 
associated with increased mortality, morbidity and length 
of hospital stay in patients presenting with a range of 
conditions. Despite this, the management of patients 
remains problematic. The prevalence of hyponatraemia in 
widely different conditions and the fact that hyponatrae-
mia is managed by clinicians with a broad variety of 
backgrounds have fostered diverse institution-and speciali-
ty-based approaches to diagnosis and treatment. To ob-
tain a common and holistic view, the European Society 
of Intensive Care Medicine (ESICM), the European So-
ciety of Endocrinology (ESE) and the European Renal 
Association-European Dialysis and Transplant Association 
(ERA-EDTA), represented by European Renal Best 
Practice (ERBP), have developed the Clinical Practice 
Guideline on the diagnostic approach and treatment of 
hyponatraemia as a joint venture of three societies rep-
resenting specialists with a natural interest in hyponat-
raemia. In addition to a rigorous approach to methodo-
logy and evaluation, we were keen to ensure that the do-
cument focused on patient-important outcomes and inclu-
ded utility for clinicians involved in everyday practice. 
 
Key words: hyponatremia, mild, moderate, severe,  
acute, chronic  
___________________________________________ 
 
Chapter 1. Introduction and Methodology 
 
Hyponatraemia, defined as a serum sodium concentration 
<135 mmol/L, is the most common disorder of body fluid 
and electrolyte balance encountered in clinical practice. 
Hyponatraemia is present in 15-20% of emergency ad-
missions to hospital and occurs in up to 20% of critica-
lly ill patients. It can lead to a wide spectrum of clinical 
symptoms, from subtle to severe or even life threatening 
and is associated with increased mortality, morbidity and 
length of hospital stay in patients presenting with a range 
of conditions. Despite this, the management of patients 
remains problematic. The prevalence of hyponatraemia 
in widely different conditions and the fact that hypo-
natraemia is managed by clinicians with a broad variety 
of backgrounds, has fostered diverse institution- and spe-
ciality-based approaches to diagnosis and treatment.  
Against this background, the European Society of Inten-
sive Care Medicine (ESICM), the European Society of 
Endocrinology (ESE) and the European Renal Association-
European Dialysis and Transplant Association (ERA-
EDTA), represented by European Renal Best Practice 
(ERBP) have developed this Clinical Practice Guideline 
on the diagnostic approach and treatment of hyponatraemia 
as a joint venture of three societies representing specialists 
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with a natural interest in hyponatraemia. In addition to a 
rigorous approach to methodology and evaluation, we 
were keen to ensure the document focused on patient-
important outcomes and had utility for clinicians 
involved in every-day practice. 
This condensed and translated version of the Clinical 
Practice Guideline on Diagnosis and Treatment of Hy-
ponatraemia focuses on recommendations on diagnosis 
and treatment of hyponatraemia. For aspects of conflict 
of interest, purpose and scope, methods of guideline 
development and pathophysiology of hyponatraemia, we 
refer to the full version of the guideline, which is free 
available on http://ndt.oxfordiournals.ore/content/29/suppl 
2/i1.full.pdf+html. 
Disclaimer: this guideline was translated with approval 
of ERBP, the official guideline body of ERA-EDTA. Ho-
wever, ERBP only takes full responsibility for the ori-
ginal full guideline in English as published in Nephrol. Dial. 
Transplant. (2014) 29 (suppl 2): i1-i39. doi: 10.1093/ndt/gfu 
040-First published online: February 25, 2014: http://ndt. 
oxfordiournals.org/content/29/suppl2/i1.full.pdf+html; 
http://european-renal-best-practice.org [1]. 
 
Chapter 2. Diagnosis of Hyponatraemia 
 
2.1. Classification of hyponatraemia 
 
2.1.1. Definition of hyponatraemia based on 
biochemical severity 
 
We define "mild" hyponatraemia as a biochemical fin-
ding of a serum sodium concentration between 130 and 
135 mmol/L as measured by ion specific electrode. 
We define "moderate" hyponatraemia as a biochemical 
finding of a serum sodium concentration between 125 
and 129 mmol/L as measured by ion specific electrode. 
We define "profound" hyponatraemia as a biochemical 
finding of a serum sodium concentration <125 mmol/L 
as measured by ion specific electrode. 
 
2.1.2. Definition of hyponatraemia based on time of 
development 
 
We define "acute" hyponatraemia as hyponatraemia that 
is documented to exist <48 hours. We define "chronic" 
hyponatraemia as hyponatraemia that is documented 
to exist for at least 48 hours. 
 
Table 1. (Table 5 of the online full document): Classification 
of symptoms of hyponatraemia 
Severity Symptom 
Moderately severe Nausea without vomiting 
 Confusion  
 Headache  
Severe  Vomiting  
 Cardio-respiratory distress 
 Abnormal and deep somnolence 
 Seizures  
 Coma (Glazgow Coma Scale ≤8) 
If the hyponatraemia cannot be classified, we consider it 
being chronic, unless there is clinical or anamnestic 
evidence of the contrary (Table 1, 2). 
 
2.1.3. Definition of hyponatraemia based on symptoms 
 
We define "moderately symptomatic" hyponatraemia as 
any biochemical degree of hyponatraemia in the presence 
of moderately severe symptoms of hyponatraemia (Table 1). 
We define "severely symptomatic" hyponatraemia as any 
biochemical degree of hyponatraemia in the presence 
of severe symptoms of hyponatraemia (Table 1). 
 
Table 2. (Table 8 of the online full document): Drugs and 
conditions associated with acute hyponatraemia  
(< 48 hours) 
hyponatraemia (< 48 hours) 
Postoperative phase 
Post-resection of the prostate, post-resection of endoscopic 
uterine surgery 
Polydipsia 
Exercise 
Recent thiazides prescription 
3,4-methyleendioxymethamfetamine (MDMA, XTC) 
Colonoscopy preparation 
Cyclophosphamide (intravenous) 
Oxytocin 
Recently started desmopressin therapy 
Recently started terlipressin, vasopressin 
 
Hyponatraemia can be classified based on different pa-
rameters, such as serum sodium concentration, rate of 
development, symptom severity, serum osmolality, and 
volume status. We intended to make the classification 
directly relevant for patient management. However, treat-
ment strategies cannot be adequately classified with 
reference to a single criterion. Hence, treatment strate-
gies have been classified according to combinations of 
these criteria. 
Published research suggests using a threshold of 48 
hours to distinguish "acute" from "chronic" hyponatraemia, 
as brain oedema seems to occur more frequently when 
hyponatraemia develops in less than 48 hours. Experi-
mental studies also suggest that the brain needs app-
roximately 48 hours to adapt to a hypotonic environ-
ment. Before adaptation, there is a risk of brain oedema, 
because the lower extracellular osmolality promotes a 
shift of water into the cells. However, once adaptation is 
completed, brain cells can again sustain damage if the 
serum sodium concentration increases too rapidly. Break-
down of the myelin sheath insulating individual neurons 
can result in what is called the osmotic demyelination 
syndrome. It is thus important to distinguish between 
acute and chronic hyponatraemia to assess whether 
someone is at greater risk of immediate brain oedema 
than of osmotic demyelination. In clinical practice, the 
distinction between acute and chronic hyponatraemia 
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is often unclear, particularly for patients presenting to the 
emergency room. If classification as acute or chronic 
is not possible or when there is doubt, it should be con-
sidered chronic, unless there are reasons to assume it 
is acute (see Table 10 of original document). 
The classification based on symptoms aims to reflect 
the degree of brain oedema and the extent of immediate 
danger. It allows matching treatment to the immediate 
risk, with more aggressive treatment for symptoms that 
are more severe. Nevertheless, a classification based only 
on symptom severity has several shortcomings, as pa-
tients may porgress from moderately severe to severe 
symptoms within hours. In addition, symptoms of hypo-
natraemia are nonspecific and clinicians need to assess 
the possibility that symptoms can be caused by conditions 
other than hyponatraemia on itself. In general, one 
should be particularly careful when attributing moderate-
ly severe to severe symptoms to hyponatraemia when 
the biochemical degree of hyponatraemia is only mild. 
Patients with hyponatraemia may be hypovolaemic, 
euvolaemic, or hypervolaemic, and many traditional 
diagnostic algorithms start with a clinical assessment 
of volume status [2] .The sensitivity and specificity of  
clinical assessments of volume status are low, poten-
tially leading to misclassification early in the diagnostic 
tree. In addition, there might be confusion regarding the  
compartment the fluid is in (circulating or extracellular). 
Therefore, we have used the terms "effective circulating 
volume" and "extracellular fluid volume" throughout the 
text to reduce ambiguity. 
 
2.2. Confirming hypotonic and excluding non-
hypotonic hyponatraemia 
 
We recommend excluding hyperglycaemic hyponatraemia 
by measuring the serum glucose concentration and co-
rrecting the measured serum sodium concentration for the 
serum glucose concentration if the latter is increased (1D). 
Hyponatraemia with a measured osmolality <275 
mOsm/kg always reflects hypotonic hyponatraemia 
(Not Graded). 
Accept as "hypotonic hyponatraemia" a hyponatraemia 
without evidence for causes of non-hypotonic hypo- 
 
Table 3. (Table 10 of the online full document): Causes of nonhypotonic hyponatraemia 
Setting Serum 
osmolality 
Examples 
Presence of "effective" osmoles 
that raise serum osmolality and can 
cause hyponatraemia 
Isotonic or  
hypertonic 
Glucose 
Mannitol 
Glycine 
Histidine-tryptophane-ketoglutarate  
Hyperosmolar radiocontrast media  
Maltose 
   
Presence of "ineffective" osmoles 
that raise serum osmolality but do 
not cause hyponatraemia 
Isotonic or 
hyperosmolar Urea 
  Alcohols 
  Ethylene-glycol 
   
Presence of endogenous solutes 
that cause pseudohyponatraemia 
(laboratory artifact) 
Isotonic Triglycerides, cholesterol, protein  
Intravenous immunoglobulins 
Monoclonal gammapathies 
 
natraemia as listed in table 3 (Not Graded). Estimates 
of the serum sodium concentration corrected for the 
presence of hyperglycaemia can be obtained from the 
following equations: 
 
 
Corrected serum (Na+) = measured (Na+) + 2.4 x (glucose (mmol/l) - 100 (mmol/l)  
100 mmol/l  
Corrected (Na+) = measured (Na+) + 2.4 x (glucose (mmol/l) - 5.5 (mmol/l)  
5.5 mmol/l  
† [Na+], serum sodium concentration; [Glucose], serum glucose concentration. 
 
 
 
This translates into adding 2.4 mmol/L to the measured 
serum sodium concentration for every 5.5 mmol/L (100 
mg/dL) incremental rise in serum glucose concentration 
above a standard serum glucose concentration of 5.5 
mmol/L (100 mg/dL). 
 
2.3. Which parameters to use for differentiating 
causes of hypotonic hyponatraemia? (Figure 1.) 
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We recommend interpreting urine osmolality of a 
spot urine sample as a first step (1D). 
If urine osmolality ≤100 mOsm/kg, we recommend 
accepting relative excess water intake as a cause of 
the hypotonic hyponatraemia (1D). 
If urine osmolality >100 mOsm/kg, we recommend in-
terpreting the urine sodium concentration on a spot urine 
sample taken simultaneously with a blood sample (1D). 
If urine sodium concentration ≤30 mmol/L, we suggest  
accepting low effective arterial volume as a cause of 
the hypotonic hyponatraemia (2D). 
If urine sodium concentration >30 mmol/L, we suggest 
assessing extracellular fluid status and use of diuretics to 
further differentiate likely causes of the hyponatraemia (2D). 
We suggest against measuring vasopressin for confir-
ming the diagnosis of SIADH (2D). 
 
 
              Fig. 1. (Figure 6 of the online full document): Algorithm for the diagnosis of hyponatraemia  
 
Advice for clinical practice 
 
Correct interpretation of laboratory measurements requires 
contemporaneous collection of blood and urine specimens. 
For practical reasons, urine osmolality and sodium concen- 
 
tration are best determined in the same urine sample. 
If clinical assessment indicates the volume of extracellu-
lar fluid is not overly increased and the urine sodium 
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concentration >30 mmol/L, exclude other causes of hy-
potonic hyponatraemia before implicating SIAD.  
 
  
Table 4. (Table 6 of the full online document): Diagnostic 
criteria for the syndrome of inappropriate antidiuresis 
Essential criteria 
Effective serum osmolality < 275 mOsm/kg 
Urine osmolality > 100 mOsm/kg at some level of decreased 
effective osmolality 
Clinical euvolaemia 
Urine sodium concentration > 30 mmol/L with normal 
dietary salt and water intake 
Absence of adrenal, thyroid, pituitary or renal insufficiency 
No recent use of diuretic agents 
Supplemental criteria 
Serum uric acid < 0.24 mmol/L (< 4 mg/dL) 
Serum urea < 3.6 mmol/L (< 21.6 mg/dL) 
Failure to correct hyponatraemia after 0.9% saline infusion 
Fractional sodium excretion > 0.5% 
Fractional urea excretion > 55% 
Fractional uric acid excretion > 12% 
Correction of hyponatraemia through fluid restriction___ 
Adapted from Schwartz WB et al. Am J Med 1957; 23: 529-
543. and Janicic N et al. Endocrinol Metab Clin North Am 
2003; 32: 459-481 [3]. 
 
Consider using the diagnostic criteria listed in Table 4 
and looking for known causes of SIAD (Table 5 and 6).  
Consider primary or secondary adrenal insufficiency 
as an underlying cause of the hypotonic hyponatraemia. 
Kidney disease complicates differential diagnosis of 
hyponatraemia. Besides possibly contributing to 
thehyponatraemia, the ability of the kidneys to 
regulate urine osmolality and urine sodium is often 
diminished, much like with the use of diuretics. 
As urine osmolality and sodium may no longer reflect 
the effects of the regular hormonal axes regulating water 
and sodium homeostasis, any diagnostic algorithm for 
hyponatraemia must be used with caution in patients  
with kidney disease. 
The water-loading test is generally not helpful for diffe-
rential diagnosis of hypotonic hyponatraemia and may be 
dangerous in this setting. 
 
Table 5. (Table 7 of the online full document): Differences between SIADH and cerebral salt 
wasting 
Malignant diseases Pulmonary disorders Disorders of the nervous system 
Carcinoma Infections Infection 
Lung Bacterial pneumonia Encephalitis 
Oropharynx Viral pneumonia Meningitis 
Gastrointestinal tract Pulmonary abscess Brain abscess 
Stomach Tuberculosis Rocky Mountain spotted fever 
Duodenum Aspergillosis AIDS 
Pancreas Asthma Malaria 
Genitourinary tract Cystic fibrosis Vascular and masses 
Ureter Respiratory failure associated 
with positive - pressure 
breathing 
Subdural hematoma 
Bladder  Subarachnoid haemorrhage 
Prostate  Stroke 
Endometrium  Brain tumors 
Endocrine thymoma  Head trauma 
Lymphomas  Other 
Sarsomas  Hydrocephalus 
Ewing's sarcoma  Cavernous sinus thrombosis 
Olfactory neuroblastoma  Multiple sclerosis 
  Guillain-Barre' syndrome 
  Shy-Drager syndrome 
  Delirium tremens 
  Acute intermittent porphyria 
AIDS, acquired immunodeficiency syndrome; MOAI, monoamine oxidase inhibitors; MDMA, 3,4-
methylenedioxymethamphetamine; NSAIDs, non-steroidal anti-inflammatory drugs; SSRIs, selective 
serotonin reuptake inhibitors 
 
Drugs Other causes 
Vasopressin release or action stimulants Hereditary  
Antidepressants  Gain-of-function mutation of the 
vasopressin V2 receptor 
SSRIs Idiopathic  
Tricyclic  Transient  
MAOI Exercise-associated  
 hyponatraemia 
Venlafaxine  General anaesthesia  
Anticonvulsants  Nausea  
Carbamazepine  Pain  
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Oxcarbazepine  Stress  
  
Sodium valproate  
Lamotrigine   
Antipsychotics   
Phenothiazides   
Butyrophenones   
Anticancer drugs  
Vinca alkaloids  
Platinum compounds  
Ifosfamide   
Melphalan   
Cyclophosphamide  
Methotrexate   
Pentostatin   
Antidiabetic drugs   
Chlorpropamide   
Tolbutamine   
Miscellaneous   
Opiates   
MDMA (XTC)  
Levamisole   
Interferon   
NSAIDs  
Clofibrate   
Nicotine   
Amiodarone   
Proton pump inhibitors  
MABs  
Vasopressin analogues  
Desmopressin   
Oxytocin   
Terlipressin   
Vasopressin   
 
Table 6. (table 11 of the online full document): Differences 
between SIADH and cerebral salt wasting 
 
SIADH 
Cerebral salt 
wasting 
Serum urea 
concetration 
Normal-low Normal-high 
Serum uric acid 
concentration 
Low  Low  
Urine volume  Normal-low High  
Urine sodium 
concentration 
>30 mmol/L >>30 mmol/L 
Blood pressure Normal 
Normal-orthostatic 
hypotension 
Central venous 
pressure 
Normal Low  
Adapted from Sherlock M et al. Clin Endocrinol 2006; 64: 
250*2S4 and Brimioulle S et al. Intensive Care Med 2008; 
34: 125-31 [5]. 
 
Chapter 3. Treatment of Hypotonic Hyponatraemia 
 
How to use the treatment recommendations? 
 
Individual recommendations and statements on manage-
ment of hyponatraemia can only be correctly interpreted 
and implemented if considered within the structure illus-
trated in figure 2. 
The guideline development group felt that with severe 
or moderately severe symptoms, the acute risk of brain 
oedema outweighs the risk of osmotic de- myelination  
syndrome. They felt it justifies urgent treatment in these 
conditions, irrespective of biochemical degree or timing 
(acute versus chronic) of hyponatraemia. Conversely, 
the guideline development group believed that in the 
absence of severe or moderately severe symptoms, there 
is time for diagnostic assessment, and cause-specific 
treatment is the most reasonable approach.  
It is crucial to understand that for correctly classifying 
symptoms as "severe" or "moderately severe", there must 
be sufficient confidence that the symptoms are caused 
by hyponatraemia itself. If hyponatraemia is mild and 
symptoms are severe or moderately severe, the guideli-
ne development group advises to only accept causa-
lity in exceptional cases. Consequently, generally, chapters 
3.1, 3.2, and 3.3 are not applicable when hyponatraemia 
is mild (see chapters 7.1, 7.2 and 7.3 full guideline pub-
lication). It is also essential to understand that the guide-
line development group distinguishes between targets 
and limits. A target is a goal one is aiming for; it is the 
change in serum sodium concentration that one wishes and 
expects to achieve with a particular treatment. In contrast, a 
limit is a change in serum sodium concentration one does 
not want to exceed and if surpassed, requires prompt coun-
ter-regulating intervention. In addition, the reader should 
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bear in mind that the absolute numbers provided as "tar-
gets" or "limits" should always be interpreted in the clini-
cal context of the individual patient. 
 
3.1. Hyponatraemia with severe symptoms 
 
3.1.1. First hour management, regardless of 
whether hyponatraemia is acute or chronic 
 
We recommend prompt intravenous infusion of 150 mL 3% 
hypertonic saline or equivalent over 20 minutes (1D). 
We suggest checking the serum sodium concentration 
after 20 minutes while repeating an infusion of 150 mL 
3% hypertonic saline or equivalent over the next 20 
minutes (2D). 
We suggest repeating the two therapeutic recommen-
dations above twice or until a target of 5 mmol/L in-
crease in serum sodium concentration is achieved (2D). 
Manage patients with severely symptomatic hyponat-
raemia in an environment where close biochemical and 
clinical monitoring can be provided (Not Graded).  
 
 
 
      Fig. 2. (Figure 7 of the online full document): Algorithm for the management of  
      hypotonic hyponatraemia* 
 
3.1.2. Follow up management in case of improvement 
of symptoms after a 5 mmol/L increase in serum sodium 
concentration in the first hour, regardless of whether 
hypo-natraemia is acute or chronic 
 
We recommend stopping the infusion of hypertonic 
saline (1D). 
We recommend keeping the intravenous line open by  
infusing the smallest feasible volume of 0.9% saline 
until cause-specific treatment is started (1D). 
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We recommend starting a diagnosis specific treatment 
if available, aiming at least to stabilize sodium con-
centration (1D). 
We recommend limiting the increase in serum sodium 
concentration to a total of 10 mmol/L during the first 
24 hours and an additional 8 mmol/L during every 24 
hours thereafter until the serum sodium concentration 
reaches 130 mmol/L (1D). 
We suggest checking the serum sodium concentration 
after 6 and 12 hours, and daily afterwards until the se-
rum sodium concentration has stabilised under stable 
treatment (2D). 
 
3.1.3 Follow up management in case of no improvement 
of symptoms after a 5 mmol/L increase in serum sodium 
concentration in the first hour, regardless of whether 
the hyponatraemia is acute or chronic 
 
We recommend continuing an intravenous infusion of 3% 
hypertonic saline or equivalent aiming for an additional 
1 mmol/L/h increase in serum sodium concentration (1D). 
We recommend stopping the infusion of 3% hyperto-
nic saline or equivalent when the symptoms improve, 
the serum sodium concentration increases 10 mmol/L 
in total or the serum sodium concentration reaches 130 
mmol/L, whichever occurs first (1D). 
We recommend additional diagnostic exploration for 
other causes of the symptoms than hyponatraemia (1D). 
We suggest checking the serum sodium concentration 
every 4 hours as long as an intravenous infusion of 3% 
hypertonic saline or equivalent is continued (2D). 
 
 
 
Advice for clinical practice 
 
Prompt infusion of hypertonic saline may save lives. 
However, preparing a 3% hypertonic saline infusion 
takes time and errors may occur in calculating the re-
quired amount of sodium chloride. Therefore, it may 
be wise for the pharmacy to store pre-prepared 150 mL 
bags of 3% hypertonic saline. It ensures that solutions 
are prepared under sterile conditions, by either the phar-
macist or the manufacturer, and are available for imme-
diate infusion without having to prepare them on the spot. 
Consider using weight based (2mL/kg) rather than the 
fixed 150 mL infusion volumes of 3% hypertonic saline 
in case of obviously deviant body composition.  
Do not expect patients with severe symptoms to comp-
letely recover immediately, as it may take some time for 
the brain to fully recover. Be aware that sometimes it 
may not be possible to assess an improvement in symp-
toms, e.g. because the patient is intubated and sedated. 
In these cases, we advise to follow guidance as described 
under 3.1.2. (see chapter (7.1.2. full guideline publication). 
Keep in mind that if hypokalaemia is present, correction 
of the hypokalaemia will contribute to an increase in 
serum sodium concentration.  
To achieve the 1 mmol/L/h increase advised in 3.1.3. (see 
chapter 7.1.3. full guideline publication)., the formula of 
Adrogue-Madias may be used, but keep in mind that the 
actual increase may exceed the calculated increase [7]: 
 
 
 
§ The numerator in formula 1 is a simplification of the 
expression in formula 2, with the value yielded by the 
equation in mmol/L. The estimated total body water 
(in litres) is calculated as a fraction of body weight. 
The fraction is 0.6 in nonelderly men and 0.5 in no-
nelderly women; and 0.5 and 0.45 in elderly men and 
women respectively. Normally, extracellular and intra-
cellular fluids account for 40% and 60% of total body 
water respectively. 
 
3.2. Hyponatraemia with moderately severe symptoms 
 
We recommend starting prompt diagnostic assess-
ment (1D). 
Stop, if possible, medications and other factors that can 
contribute to or provoke the hyponatraemia (Not Graded). 
We recommend cause-specific treatment (1D). 
We suggest immediate treatment with a single intra-
venous infusion of 150 mL 3% hypertonic saline or 
equivalent over 20 minutes (2D). 
We suggest aiming for a 5 mmol/L/24 h increase in se-
rum sodium concentration (2D). 
We suggest limiting the increase in serum sodium con-
centration to 10 mmol/L in the first 24 hours and 8 mmol/L 
during every 24 hours thereafter, until a serum sodium 
concentration of 130 mmol/L is reached (2D). 
We suggest checking the serum sodium concentration 
after one, 6 and 12 hours (2D). 
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We suggest additional diagnostic exploration for other 
causes of the symptoms if the symptoms do not improve 
with an increase in serum sodium concentration (2D). 
We suggest considering to manage the patient as in se-
verely symptomatic hyponatraemia if the serum sodium 
concentration further decreases despite treating the un-
derlying diagnosis (2D). 
3.3. Acute hyponatraemia without severe or moderately 
severe symptoms 
 
Make sure that the serum sodium concentration has 
been measured using the same technique as used for 
the previous measurement and that no administrative 
errors in sample handling have occurred (Not Graded). 
If possible, stop fluids, medications and other factors 
that can contribute to or provoke the hyponatraemia 
(Not Graded). 
We recommend starting prompt diagnostic assessment (1D). 
We recommend cause-specific treatment (1D). 
If the acute decrease in serum sodium concentration 
exceeds 10 mmol/L, we suggest a single intravenous in-
fusion of 150 mL 3% hypertonic saline or equivalent 
over 20 minutes (2D). 
We suggest checking the serum sodium concentration 
after four hours, using the same technique as used for 
the previous measurement (2D). 
 
3.4. Chronic hyponatraemia without severe or 
moderately severe symptoms 
 
3.4.1. General management 
 
Stop non-essential fluids, medications and other factors 
that can contribute to or provoke the hyponatraemia 
(Not Graded). 
We recommend cause-specific treatment (1D). 
In mild hyponatraemia, we suggest against treatment 
with the sole aim of increasing the serum sodium 
concentration (2C). 
In moderate or profound hyponatraemia, we reco-
mmend avoiding an increase in serum sodium concen-
tration of >10 mmol/L during the first 24 hours and >8 
mmol/L during every 24 hours thereafter (1D). 
In moderate or profound hyponatraemia, we suggest 
checking the serum sodium concentration every six 
hours until the serum sodium concentration has 
stabilised under stable treatment (2D). 
In case of unresolved hyponatraemia, reconsider the diag-
nostic algorithm and ask for expert advice (Not Graded). 
 
3.4.2. Patients with expanded extracellular fluid 
 
We recommend against a treatment with the sole aim 
of increasing the serum sodium concentration in mild 
or moderate hyponatraemia (1C). 
We suggest fluid restriction to prevent further fluid 
overload (2D). 
We recommend against vasopressin receptor anta-
gonists (1C). 
We recommend against demeclocycline (1D). 
 
 
 
 
3.4.3. Patients with syndrome of inappropriate 
antidiuresis 
 
In moderate or profound hyponatraemia, we suggest 
restricting fluid intake as first- line treatment (2D). 
In moderate or profound hyponatraemia, we suggest the 
following can be considered equal second line treat-
ments: increasing solute intake with 0.25 to 0.50 g/kg/day 
of urea or a combination of low dose loop diuretics 
and oral sodium chloride (2D). 
In moderate or profound hyponatraemia, we reco-
mmend against lithium or demeclocycline (1D). 
In moderate hyponatraemia, we do not recommend 
vasopressin receptor antagonists (1C). 
In profound hyponatraemia, we recommend against 
vasopressin receptor antagonists (1C). 
 
3.4.4. Patients with contracted circulating volume 
 
We recommend restoring extracellular volume with 
intravenous infusion of 0.9 % saline or a balanced 
crystalloid solution at 0.5 to 1.0 mL/kg/h (1B). 
Manage patients with haemodynamic instability in an 
environment where close biochemical and clinical mo-
nitoring can be provided (Not Graded). 
In case of haemodynamic instability, the need for rapid 
fluid resuscitation overrides the risk of an overly rapid 
increase in serum sodium concentration (Not Graded). 
 
Advice for clinical practice 
 
A sudden increase in urine output to >100 mL/h signals 
increased risk of overly rapid rise in serum sodium con-
centration. If vasopressin activity is suddenly suppre-
ssed, as happens when intravascular volume is restored 
in hypovolaemia, free water clearance can dramatically 
increase, resulting in serum sodium concentrations rising 
more rapidly than expected. If urine output suddenly in-
creases, we would advise measuring the serum sodium 
concentration every two hours until it has stabilised under 
stable treatment. The implicit advice to monitor urine 
output does not imply we advise a bladder catheter so-
lely for this purpose. Most patients will be able to void 
spontaneously and collect urine for output monitoring.  
As a means of increasing solute intake, we suggest daily 
intake of 0.25 to 0.50 g/kg urea can be used. The bitter 
taste can be reduced by combining it with sweet tas-
ting substances. The pharmacist may be asked to pre-
pare the following as sachets: urea 10 g+NaHCO3 2 
g+citric acid 1.5 g+sucrose 200 mg, to be dissolved in 
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50 to 100 mL water. This will result in a more pala-
table, slightly sparkling solution.  
 
 
 
 
 
3.5. What to do in case hyponatraemia is corrected 
too rapidly? 
 
We recommend prompt intervention for relowering the 
serum sodium concentration if it increases >10 mmol/L 
during the first 24 hours or >8 mmol/L in any 24 hours 
thereafter (1D). 
We recommend discontinuing the ongoing active 
treatment (1D). 
We recommend consulting an expert to discuss if it is 
appropriate to start an infusion of 10 mL/kg body weight 
of electrolyte-free water (e.g. glucose solutions) over 
one hour under strict monitoring of urine output and 
fluid balance (1D). 
We recommend consulting an expert to discuss if it is 
appropriate to add intravenous desmopressin 2 g, with 
the understanding that this should not be repeated more 
frequently than every 8 hours (1D). 
The guideline development group wants to underscore 
that these symptoms can also be induced by other con-
ditions. Clinical and anamnestic data should be taken 
into account when assessing the causal relation between 
the hyponatraemia and a certain symptom (i.e. to assess 
whether the symptom has been caused by the hyponat-
raemia or the hyponatraemia by the underlying condi-
tion/symptom). The less pronounced (e.g. mild) the bio-
chemical degree of hyponatraemia, the more caution 
should be taken when considering that the hyponatraemia 
is the cause of the symptoms. This list is not exhaus-
tive, and all symptoms that can be signs of cerebral 
oedema should be considered as severe or moderate 
symptoms that can be caused by hyponatraemia.  
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